EFFECT OF PRENATAL ADMINISTRATION OF THERAPEUTIC DOSE OF TOPIRAMATE ON PLACENTAE ALBINO RATS' FETUSES
Keywords:Caspase-3, Nil, Placenta, Topiramate
Objective: Topiramate is an antiepileptic drug (AED) used for the treatment of partial seizure in adult and children epileptic patients. It passed through the placenta causing a birth defect. However, little literature focused on placental alteration due to the administration of topiramate during pregnancy. So, applying different predictive parameters; placental weight, histopathological (Haematoxylin and Eosin), histochemical (periodic acid Schiff's) and immunohistochemistry (Caspase-3).
Methods: Topiramate was orally administrated to the pregnant rats with dose 100 mg/kg rats from 5th to 19th day of gestation. The dam's undergone hysterectomy and the placentae were weighted and stained by Haematoxylin and Eosin, periodic acid Schiff's and Caspase-3.
Results: The study indicated that there is statistically significant (P<0.05) increase in the treated placental weight (0.4717Â±0.03788) compared with control group (0.5208Â±0.02930). Also, the light microscopic examination of the placental specimens using Haematoxylin and Eosin staining revealed that an alteration in both basal and labyrinth zone. Apoptotic feature in spongiotrophoblast and trophoblasts is detected. Positive Periodic acid Schiff's reaction for polysaccharides in the topiramate-treated group. Caspase-3 is showing apoptotic cells in the trophoblast layer.
Conclusion: Long-term daily use of topiramate during pregnancy can lead to obvious pathological histotoxic effects in layers of placenta tissues which may be implicated in cognitive affection. Various effects of topiramate necessitate further investigations.
Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. American academy of neurology; American epilepsy society, management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology subcommittee of the American academy of neurology and the American epilepsy society. Epilepsia 2009;50:1237â€“46.
Palmieri C, Canger R. Teratogenic potential of newer antiepileptic drugs: What is known and now should this influence prescribing. CNS Drugs 2002;16:755-64.
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, et al. A comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010;38:D237-43.
Aithal S, Hooli TV, Patil R, Varun HV, Swetha ES. Evaluation of the antidepressant activity of topiramate in mice. Asian J Pharm Clin Res 2014;7:174-6.
Gentile S. Topiramate in pregnancy and breastfeeding. Clin Drug Investig 2009;29:139â€“41.
Ohman I, Vitols S, Luef G, SÃ¶derfeldt B, Tomson T. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002;43:1157-60.
Fountain NB. A pregnant pause to consider teratogenicity of topiramate. Epilepsy Curr 2009;9:36â€“8.
Khouri NA. Reproductive toxic effects of Topamax ingestion in female sprangue dawley rats. Neuroendocrinol Lett 2005; 26:843-7.
Hagar AH. Histopathologic effect of prenatal topiramate exposure on rat cerebral cortex and hippocampus. J Interdiscipl Histopathol 2014;2:61-8.
Bender P. Genetics of cleft lip and palate. J Pediatric Nursing 2000;15:242-9.
Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305:1996-2002.
Vajda FJ, Hitchcock A, Graham J, Oâ€™Brien T, Lander C, Eadie M. The Australian register of antiepileptic drugs in pregnancy: the ï¬rst 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007;47:468-74.
Hernandez-Diaz S, Mittendorf R, Holmes LB. Comparative safety of topiramate during pregnancy. Birth Defects Res Part A 2010;408:20.
Singh M, Mishra A. Topiramate induced congenital malformations in rats. Natl Acad Sci Lett 2009;32:195â€“200.
Vila CerÃ©n C, Demestre Guasch X, Raspall Torrent F, Elizari Saco MJ, Sala CastellvÃ P, MartÃnez Nadal S. Topiramate and pregnancy. Neonate with bone anomalies. Annals Pediatrics (Barc) 2005;63:363-5.
Kwarta RF, Hulihan JF, Schmider J, Nye JS. Pregnancy outcomes in topiramate-treated women. Epilepsia 2006;47:119-204.
Fadel RA, Sequeira RP, Abu-Hijleh MF, Obeidat M, Salem AHA. Effect of prenatal administration of therapeutic doses of topiramate on the ossification of ribs and vertebrae in rat fetuses. Rom J Morphol Embryol 2012;53:321â€“7.
Creagh EM, Martin SJ. Caspase: cellular demolition experts. Biochem Soc Trans 2001;29:696â€“702.
McClain RM, Becker BA. Teratogenicity, foetal toxicity and placental transfer of lead nitrate in rats. Toxicol Appl Pharmacol 1975;931:72-82.
El-Ghareeb AA, Salah EL-Din EY, Omar AR, Atallah SE. Evaluate the effect of oral administration of Salvia officinalis extracts on albino rats' fetuses during the gestation period. Int J Adv Life Sci 2016;9:307-15.
WHO (World Health Organization). Principles for evaluating health risks to reproduction associated with exposure to chemicals. Environ Health Criteria 2001;225:1-187.
Banchroft JD, Stevens A. The haematoxylin and eosin. Theory and practice of histological techniques. 4th ed. London, New York, Tokyo: Churchill Livingstone 1996. p. 99â€“112.
Kiernan JA. Histological and histochemical methods: Theory and practice. Pergamon Press Inc New York USA; 1981.
Karakus EA, Karadeniz N, Simsek I, Can KA, Kara A, Yildirim S, et al. Protective effect of panax ginseng against serum biochemical changes and apoptosis in the liver of rats treated with carbon tetrachloride (CCl4). J Hazard Mater 2011; 195:208â€“13.
Singh M, Mishra A. Teratogenicity of topiramate in rats. J Am Soc Inf Sci Technol 2005;54:206.
Fadel RA, Dessouki SKM, Mostafa NMM, Dawoud AWAK. Skeletal development in albino rat fetuses following maternal exposure to diazepam. Egyptian J Anat 2002;25:233â€“55.
Saillenfait AM, Gallissot F, SabatÃ© JP. Developmental toxic effects of N-ethyl-2-pyrrolidone administered orally to rats. J Appl Toxicol 2007;27:491â€“7.
Glauser TA. Topiramate. Epilepsia 1999;5:71-80.
Reimers A, Helde G, BrÃ¥then G, Brodtkorb E. Lamotrigine and its N 2-glucuronide during pregnancy: the significance of renal clearance and estradiol. Epilepsy Res 2011;94:198â€“205.
Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005;44:10â€“1008.
Ornoy A, Rand SB, Bischitz N. Hyperglycemia and hypoxia are interrelated in their teratogenic mechanism: studies on cultured rat embryos. Birth Defects Res Part B 2010;89:106â€“15.
Fadel RAR, Omar MM, Issa FI, Badr FM. Effects of melatonin on the teratogenicity of alcohol in the albino rat. Suez Canal University Med J 1999;2:173â€“86.
NaziroÄŸlu M, Kutluhan S, UÄŸuz AC, Celik O, Bal R, Butterworth PJ. Topiramate and vitamin E modulate the electroencephalographic records, brain microsomal and blood antioxidant redox system in the pentylenetetrazol-induced seizure of rats. J Membr Biol 2009;229:131â€“40.
Chen YS, Lim SC, Chen MH, Quinlan RA, Perng MD. Alexander disease-causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability. Exp Cell Res 2011;317:2252â€“66.
Tung EWY, Winn LM. Epigenetic modification in valproic acid-induced teratogenesis. Toxicol Appl Pharmacol 2010;248:201-9.
Menegola E, Di Renzo F, Broccia ML, Prudenziati M, Minucci S, Massa V, et al. Inhibition of histone deacetylase activity on specific embryonic tissue as a new mechanism for teratogenicity. Birth Defect Res Part B 2005;74:392-8.
Di Renzo F, Broccia ML, Giavini E, Menegola E. VPA-related axis skeletal defects and apoptosis: a proposed event cascade. Reprod Toxicol 2010;29:106-12.
Margulis AV, Mitchell AA, Gilboa SM, Werler MM, Mittleman MA, Glynn RJ, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:1. e1-1. e7.
MartÃnez-FrÃas ML. Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology 2009;72:2054-5.
Tata AL, Kockler DR. Topiramateforbingeeating disorder associated with obesity. Ann Pharmacother 2006;40:1993-7.
McNamara JO. Pharmacotherapy of the epilepsies. Chapter 19. In: Brunton LL, Parker KL, Murri N. eds. Goodman and Gilmanâ€™s the pharmacological basis of therapeutics, 11e. Available from: http://www.accessmedicine.com.ezp-prod1.hul.harvard.edu/ content.aspx?aID939716. [Last accessed on 20 Dec 2011]
Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acidâ€“base balance: extent, mechanism and effects, Br J Clin Pharmacol 2009;68:655â€“61.
Paul E, Conant KD, Dunne IE, Pfeifer HH, Lyczkowski DA, Linshaw MA, et al. Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. Epilepsy Res 2010;90:151â€“6.